Novel Agents in the Treatment of Lung Cancer:
Advances in EGFR-targeted Agents
Third Cambridge Conference
September 2005
The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to EGFR Kinase Inhibitors
Jeffrey A. Engelman and Lewis C. Cantley
Her2-Targeted Therapies in Non–Small Cell Lung Cancer
Charles Swanton, Andy Futreal, and Tim Eisen
Genomic Approaches to Lung Cancer
Roman K Thomas, Barbara Weir, and Matthew Meyerson
"Oncogenic Shock": Explaining Oncogene Addiction through Differential Signal Attenuation
Sreenath V. Sharma, Michael A. Fischbach, Daniel A. Haber, and Jeffrey Settleman
Mouse Models of Lung Cancer
Amit Dutt and Kwok-Kin Wong
EGFR Mutation Testing in the Care of Lung Cancer Patients
Lecia V. Sequist, Victoria A. Joshi, Pasi A. Jänne, Daphne W. Bell, Panos Fidias, Neal I. Lindeman, David N. Louis, Jeffrey C. Lee, Eugene J. Mark, Janina Longtine, Peter Verlander, Raju Kucherlapati, Matthew Meyerson, Daniel A. Haber, Bruce E. Johnson, and Thomas J. Lynch
Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and FISH – Why, When, and How?
Rafal Dziadziuszko, Fred R. Hirsch, Marileila Varella-Garcia, and Paul A. Bunn, Jr.
Impact of EGFR Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Pasi A. Jänne and Bruce E. Johnson
Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Alan Sandler and Roy Herbst
Strategies to Enhance Epidermal Growth Factor Inhibition: Targeting the Mevalonate Pathway
Jim Dimitroulakos , Ian A. Lorimer and Glenwood Goss
The Evolving Role of Cetuximab in Non-Small Cell Lung Cancer
Rogerio C. Lilenbaum
Rationale for a Phase II Trial of Pertuzumab, a HER2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Bruce E. Johnson, and Pasi A. Jänne
EGFR Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
John V. Heymach, Monique Nilsson, George Blumenschein, Vassiliki Papadimitrakopoulou, and Roy Herbst
Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition
Alex A. Adjei
Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer
David H. Johnson
